Incyte Corporation

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$74Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
42,891clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $4.3M
2020 $3.0M
2021 $6.5M
2022 $21M
2023 $14M
2024 $12M
2025 $13M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Dermatology $31M
Hematology & Oncology $17M
Medical Oncology $6.3M
Hematology (Internal Medicine) $2.7M
Physician Assistant $2.5M
Medical $1.6M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
John Harris Worcester, MA Dermatology $14,898,411.63
Ethan Lerner Charlestown, MA Dermatology $1,685,522.42
Serge Alexanian Los Angeles, CA Anatomic Pathology & Clinical Pathology $889,609.99
Ahmed Galal Morristown, NJ Hematology (Internal Medicine) $732,626.12
Mohamad Khair Khasawneh Maywood, IL Hematology & Oncology $665,047.80
Hana Safah Baton Rouge, LA Hematology & Oncology $631,773.43
Amit Mehta Cary, NC Hematology & Oncology $529,816.96
Salman Fazal Pittsburgh, PA Hematology & Oncology $519,805.91
Jason Salganick Phoenix, AZ Medical Oncology $517,157.49
Suresh Ratnam Mcallen, TX Medical Oncology $500,883.61

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.